Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up – Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares gapped up prior to trading on Friday . The stock had previously closed at $4.25, but opened at $4.43. Recursion Pharmaceuticals shares last traded at $4.51, with a volume of 5,005,488 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RXRX. Needham & Company LLC dropped their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Finally, Morgan Stanley dropped their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.60.

Recursion Pharmaceuticals Trading Up 7.3%

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The business has a 50-day moving average of $5.34 and a 200-day moving average of $6.59. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -2.98 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same period in the prior year, the firm posted ($0.39) EPS. Recursion Pharmaceuticals’s revenue was up 7.2% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals during the fourth quarter worth about $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals during the fourth quarter worth about $27,000. AlphaQuest LLC bought a new position in Recursion Pharmaceuticals during the first quarter worth about $36,000. GAMMA Investing LLC grew its holdings in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after acquiring an additional 1,353 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.